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Abstract
Background: Casein glycomacropeptide is a peptide that lacks phenylalanine, tyrosine, and tryptophan. This profile may 
enable it to deplete phenylalanine, tyrosine, and tryptophan, and subsequently the synthesis of dopamine and serotonin in 
the brain. Dopamine- and serotonin-depleting amino acid mixtures have shown promise as acute antimanic treatments. In 
this study, we explore the depleting effects on amino acids, dopamine and serotonin as well as its actions on manic-like and 
other behavior in rats.
Methods: Casein glycomacropeptide and a selection of amino acid mixtures were administered orally at 2, 4, or 8 h or for 1 
week chronically. Amino acid and monoamine levels were measured in plasma and brain and behavior was assessed in the 
amphetamine-hyperlocomotion, forced swim, prepulse inhibition, and elevated plus maze tests.
Results: Casein glycomacropeptide induced a time-dependent reduction in tyrosine, tryptophan, and phenylalanine in 
brain and plasma which was augmented by supplementing with leucine. Casein glycomacropeptide + leucine reduced 
dopamine in the frontal cortex and serotonin in the hippocampus, frontal cortex, and striatum after 2 and 4  h. Casein 
glycomacropeptide + leucine also had antimanic activity in the amphetamine-induced hyperlocomotion test at 2 h after a 
single acute treatment and after 1 week of chronic treatment.
Conclusions: Casein glycomacropeptide-based treatments and a branched-chain amino acid mixture affected total tissue 
levels of dopamine in the frontal cortex and striatum and serotonin in the frontal cortex, striatum, and hippocampus of rats 
in a time-dependent fashion and displayed antimanic efficacy in a behavioral assay of mania.
Keywords: casein glycomacropeptide, branched-chain amino acids, dopamine depletion, serotonin depletion, tyrosine 
depletion, tryptophan depletion, mania
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Introduction
Bipolar disorder is a serious condition with an estimated life-
time prevalence rate ranging from 2.8% to 6.5% (Bauer and 
Pfennig, 2005). Although the biological mechanism by which 
mania occurs is not yet known, the antimanic efficacy of dopa-
minergic D2 receptor antagonists as well as the dopaminergic 
resemblance of manic symptoms (e.g., experience of extreme 
and intense energy, a reduced need for sleep, increased talk-
ativeness) suggest that an overactivity in dopamine (DA) neuro-
transmission may play a role. Recent in vivo imaging evidence 
also suggests a contributory role for DA in mania (Jauhar et al., 
2017). Antipsychotics are currently the fastest acting drugs for 
treating mania, with a 30% reduction on a mania rating scale 
(YMRS) occurring within 7  days, and a 50% to 60% reduction 
after 4 weeks (Tohen et al., 2000). Antipsychotics have problem-
atic and potentially serious side effects at therapeutic doses, 
such as extrapyramidal symptoms and metabolic disturbances 
(e.g., weight gain, hyperlipidemia, hyperglycemia).
Interestingly, 2 clinical studies have reported that the deple-
tion of brain levels of the DA precursor amino acids (AAs), Phe 
and Tyr, by consuming an AA mixture that lacks Phe and Tyr 
(McTavish et  al., 2001b) or a mixture of branched-chain amino 
acids  (BCAAs), that is, leucine (Leu), isoleucine (Ile), and valine 
(Val) (Scarna et al., 2003), produces a rapid improvement in manic 
symptoms (within 6 hours) and has a persistent benefit for 1 
week with daily treatment, although it should be noted that these 
patients were in many cases still receiving their usual antimanic 
and/or psychotic drug treatments, and the observed effects can 
therefore not be attributed solely to the AA-depleting mixtures.
The same depleting AA mixtures have also been shown to 
inhibit amphetamine-induced manic behavior and DA neuro-
transmission in humans (McTavish et al., 1999b, 2001b; Leyton 
et al., 2004) and rats (McTavish et al., 1999a, 2001a; Le Masurier 
et  al., 2004, 2006; Jaskiw et  al., 2006; Bongiovanni et  al., 2008, 
2012; Brodnik et al., 2013). Together, these preliminary observa-
tions suggest that the depletion of Tyr and Phe in the brain by 
dietary means could have potential as a nutritional supplemen-
tary treatment for acute mania.
The depletion of tryptophan (Trp) by consuming a Trp-free AA 
drink has also been shown to improve mania ratings (Applebaum 
et al., 2007), but although Trp depletion does not appear to affect 
mood in healthy subjects (Benkelfat et  al., 1994), depressed 
patients in remission receiving selective serotonin reuptake 
inhibitors (Van der Does, 2001) or people with a family history of 
depression (Benkelfat et al., 1994; Klaassen et al., 1999) have been 
shown to experience depression symptoms during acute Trp 
depletion. A selective depletion of Tyr may therefore be desirable.
Free AA mixtures have a notoriously foul taste that hampers 
compliance and tolerability. Casein glycomacropeptide (CGMP) 
(e.g., Lacprodan CGMP-20, Arla Foods Ingredients Group P/S) is 
a protein isolated from whey during the cheese-making pro-
cess. It lacks Phe, Tyr, and Trp and is rich in large neutral amino 
acids (LNAAs) such as threonine (Thr) and isoleucine (Ile) (see 
Table 1), which compete with Phe, Tyr, and Trp (and other large 
neutral amino acids or LLNAs) for entry at the same active AA 
transporter in the blood-brain barrier. CGMP is currently used 
as a protein supplement for phenylketonuria patients. However, 
its unique AA profile could be used to deplete brain levels of 
Phe, Tyr, and Trp. With the benefit of improved compliance due 
to better palatability and based on the promising, rapid effects 
observed with AA-based depletion strategies in manic patients 
(McTavish et al., 2001b; Scarna et al., 2003), CGMP could be use-
ful as a dietary treatment for acute manic attacks. This has also 
been previously suggested (Badawy, 2013).
In this study, we used rats to investigate (1) whether CGMP 
(with or without added Leu) depletes Phe, Tyr, and Trp in plasma 
and brain tissue and whether DA and/or 5-HT levels in the brain 
are affected; (2) the time dependency of any such effects; (3) 
whether CGMP supplemented with Trp can prevent depletion of 
5-HT; and (4) whether CGMP has activity in behavioral tests for 
mania, anxiety, depression, and schizophrenia.
Methods And Materials
Animals
Male Sprague Dawley rats weighing approximately 300 g (7–8 weeks 
old) on the day of testing were obtained from Taconic and housed 
in pairs in acrylic cages (Cage 1291H Eurostandard Type III H, 
425 × 266 × 185 mm, Techniplast) under a 12-hour light cycle (lights 
on from 05:00 to 17:00) in a temperature- (20 ± 2ºC) and humidity-
controlled (60 ± 5%) environment. All animals were kept in the 
same room with the aforementioned conditions for at least 1 week 
before the start of each experiment. Each cage had bedding mater-
ial made of wooden chips, and the animals had access to a wooden 
stick to bite, nesting material, and metallic tunnel shelter. The 
animal rooms and all experimental facilities were protected from 
outside noise. The behavioral procedures were carried out in spe-
cially equipped rooms in the animal facility between 8:00 and 10:00 
pm. Food and water were available ad libitum. Twenty-four hours 
before sample collection or behavioral testing, rats were given a 
low protein diet (9% crude protein, Sniff) to minimize experimen-
tal variation due to differences in dietary protein intake. Different 
cohorts of rats were used for the different behavioral tests, so that 
each rat was exposed to only one test, except for locomotor activity 
that was measured prior to the forced swim test. All animal proce-
dures were approved by The Danish National Committee for Ethics 
in Animal Experimentation (2012-15-2934-00254).
Treatments
CGMP (Lacprodan CGMP-20), Leu, Ile, Val, Trp, and whey protein 
(Lacprodan DI-9224) was supplied by Arla Foods Ingredients 
Group P/S and all AAs were the l-enantiomer. The treatments 
were dissolved in tap water, the pH neutralized and administered 
via a Teflon feeding tube (18G/75 mm, Agntho’s) in a volume of 
10 mL/kg. For the amphetamine-induced hyperlocomotion (AIH) 
test, d-amphetamine hemisulfate salt (Sigma Aldrich) was dis-
solved in saline and administered i.p. at a dose of 1 mg/kg and a 
volume of 1 mL/kg. All solutions were prepared freshly each day.
Significance Statement
Casein glycomacropeptide (CGMP) is a peptide that lacks phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp), a profile that 
may enable it to deplete Phe, Tyr, and Trp, and subsequently the synthesis of dopamine (DA) and serotonin (5-HT) in the brain.
In the present work, a new dietary intervention paradigm in acute mania based on casein glycomacropeptide is proposed. The 
mechanism relies on rapid changes in brain and peripheral amino acid and monoaminergic levels in a time-dependent fashion. 
The observed changes correlate with antimanic efficacy in a behavioral assay of mania.
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Dose Selection
The doses selected for CGMP in this study were based on other 
rat depletion studies where AA mixtures lacking Phe and Tyr 
(McTavish et  al., 1999a, 2001a; Le Masurier et  al., 2004; Jaskiw 
et al., 2006; Bongiovanni et al., 2008, 2012; Brodnik et al., 2013) 
or BCAA mixtures (Le Masurier et al., 2006) were used. In these 
studies, total AA amounts of 1000 mg/kg were administered i.p. 
In this study, we opted for oral administration and a CGMP dose 
of 1500 mg/kg. CGMP formulations that could be effectively used 
in humans have been described in detail (Badawy, 2013). The 
doses chosen for the BCAAs (Le Masurier et al., 2006) and Trp 
(Le Masurier et al., 2006) were based on previous depletion stud-
ies in rats. Table 2 ahows the Amino Acid Composition of CGMP 
(Lacprodan CGMP-20) and Whey Protein (Lacprodan DI-9224) and 
the Amounts of Amino Acids Received by a 300-g Rat at a Dose of 
1500 mg/kg. Table 3 shows the Amino Acid Doses Received by a 
300-g Rat for Amino Acid-Depleting Treatments.
Sample Collection
The animals were beheaded with a sharp guillotine without 
anesthesia whereafter blood and brain samples were collected. 
Trunk blood was collected into K3-EDTA coated tubes (Terumo, 
Venosafe) standing in ice. Tubes were quickly inverted and 
centrifuged at 3400 x g for 10 min at 4°C. The resulting plasma 
fraction and brain tissues were stored at -80°C until analysis. 
Hippocampus, frontal cortex, and striatum regions were rapidly 
dissected on ice, snap-frozen with dry ice, and stored at -80°C 
until analysis. The hippocampus was dissected as the ventral 
and dorsal regions between anterior-posterior coordinates (AP) 
of approximately -1.92 mm and -6.84 mm from bregma (Paxinos 
and Watson, 2014). The frontal cortex was dissected as the cor-
tex area between approximately AP = 6.12  mm and 2.52  mm 
from bregma. The striatum was dissected as the dorsal (caudate 
putamen) and ventral (nucleus accumbens) regions between 
approximately AP = 3.72 mm and 0.36 mm from bregma.
Table 1. The Time-Dependent Effects on Tryptophan, Tyrosine, and Other Large Neutral Amino Acid Levels in Plasma, Hippocampus, Prefrontal 
Cortex, and Striatum by CGMP (1500 mg/kg) + Leu (300 mg/kg), CGMP (1500 mg/kg) + Leu (300 mg/kg) + Trp (45 mg/kg), and BCAA Mixture (Leu 
600 mg/kg + Ile 450 mg/kg + Val 450 mg/kg)
CGMP1500 + Leu300 CGMP1500 + Leu300 + Trp45 BCAA Mix
2 h 4 h 8 h 2 h 4 h 8 h 2 h 4 h 8 h
Pl
as
m
a
Histidine 80.36 ± 3.2 76.2 ± 4.3 101.2 ± 9.0 78.7 ± 2.8 81.5 ± 4.4 103 ± 4.2 91.5 ± 7.3 88.4 ± 7.0 100.9 ± 6.8
Isoleucine 186.2 ± 12.2 124.8 ± 13.8 109.5 ± 7.7 163.7 ± 10.0 123.5 ± 2.9 110 ± 3.5 485.7 ± 46.8 240.1 ± 25.8 136.4 ± 12.5
Leucine 248.4 ± 18.0 147.7 ± 12.4 113.1 ± 9.5 198.1 ± 13.4 148.9 ± 5.0 118.9 ± 5.3 420.4 ± 42.6 245.6 ± 29.8 133.6 ± 12.4
Methionine 84.4 ± 8.6 97.5 ± 6.1 110.4 ± 4.6 88.0 ± 9.5 107.4 ± 3.6 112.9 ± 4 60.3 ± 8.9 81.3 ± 6.4 96.4 ± 3.3
Phenylalanine 48.6 ± 4.3 73.0 ± 6.3 110.6 ± 7.9 54.0 ± 5.2 73.1 ± 6.7 113.7 ± 4.7 58.3 ± 5.3 80.9 ± 5.7 105.6 ± 3.3
Threonine 345.4 ± 25.5 267.6 ± 29.2 247.2 ± 20.4 317.3 ± 19.9 324.8 ± 20.3 292.5 ± 27.5 80.4 ± 8.3 72.8 ± 4.8 65.1 ± 5.6
Tryptophan 60.8 ± 4.7 70.1 ± 5.8 101 ± 7.7 201.1 ± 9.8 148.0 ± 7.8 114.8 ± 7 69.5 ± 6.1 88.3 ± 6.6 111.6 ± 10.4
Tyrosine 36.1 ± 5.2 37.2 ± 1.8 78.7 ± 8.4 49.2 ± 4.6 40.1 ± 4.2 80.1 ± 3.1 32.6 ± 3.9 40.7 ± 3.7 66.6 ± 4.5
Valine 130.4 ± 10.0 124.3 ± 19.8 105.2 ± 7.2 112.5 ± 7.3 108.1 ± 2.7 104.5 ± 2.6 560.1 ± 58.7 297.3 ± 24.6 148.5 ± 15.2
H
ip
p
oc
am
p
u
s
Histidine - 75.6 ± 18.5 90.2 ± 5.5 - 72.2 ± 15.2 85.5 ± 5.3 - 106.6 ± 35.2 82.7 ± 7.8
Isoleucine 142.1 ± 9.0 109.5 ± 7.8 101.1 ± 3.1 134.5 ± 9.0 107.6 ± 7.5 99.3 ± 2.8 264.5 ± 23.8 185.6 ± 7.5 116.1 ± 5.9
Leucine 152.8 ± 11.1 122.3 ± 6.0 101.5 ± 3.3 136.7 ± 10.1 121.5 ± 7.6 104.9 ± 4.1 179.1 ± 12.0 143.9 ± 7.8 110.3 ± 3.9
Methionine 104.1 ± 6.4 97.9 ± 3.5 104.9 ± 2.7 102.2 ± 5.6 96.6 ± 5.1 107.8 ± 4.9 103.8 ± 7.2 91.0 ± 4.9 99.2 ± 4.5
Phenylalanine 40.2 ± 2.7 65.1 ± 3.3 100.0 ± 2.7 44.6 ± 2.7 54.7 ± 5.5 99.1 ± 4.8 35.5 ± 3.4 47.9 ± 3.7 87.8 ± 6.0
Threonine 155.2 ± 9.0 200.9 ± 15.2 165.7 ± 8.5 156.1 ± 7.1 199 ± 13.3 179 ± 8.9 90.2 ± 6.6 62.8 ± 4.4 65.3 ± 3.3
Tryptophan 31.8 ± 3.4 57.7 ± 3.9 94.6 ± 5.3 144.0 ± 5.3 133.7 ± 5.7 110.9 ± 8.7 28.4 ± 1.5 49.4 ± 2.9 81.9 ± 6.3
Tyrosine 28.9 ± 2.2 30.7 ± 1.7 66.2 ± 4.2 36.2 ± 2.3 26.0 ± 1.3 66.3 ± 4.4 17.7 ± 1.2 22.0 ± 1.9 51.4 ± 4.4
Valine 105.6 ± 5.5 95.3 ± 3.5 94.9 ± 2.8 99.3 ± 5 89.6 ± 5.6 91.2 ± 2.5 298.0 ± 15.5 215.2 ± 9.0 127.4 ± 7.4
Fr
on
ta
l 
co
rt
ex
Histidine 40.3 ± 2.9 49.2 ± 4.2 75.1 ± 5.5 35.4 ± 2.0 43.0 ± 2.2 76.7 ± 3.8 31.9 ± 4.0 44.8 ± 3.6 72.8 ± 7.8
Isoleucine 121.5 ± 5.8 111.1 ± 10.1 112.8 ± 7.6 112.8 ± 4.7 104.5 ± 12.7 100.0 ± 5.1 213.8 ± 11.1 155.1 ± 8.4 147.8 ± 17.5
Leucine 126.0 ± 4.8 123.2 ± 3.0 116.0 ± 12.4 112.3 ± 3.3 121.0 ± 4.3 107.5 ± 7.2 144.4 ± 6.6 144.5 ± 7.0 126.3 ± 13.9
Methionine 87.2 ± 1.8 97.2 ± 2.0 116.7 ± 5.0 83.7 ± 3.2 95.0 ± 2.5 106.9 ± 6.3 85.7 ± 2.5 91.4 ± 3.2 106.9 ± 4.6
Phenylalanine 39.1 ± 2.0 73.4 ± 3.1 113.6 ± 7.2 40.7 ± 4.1 64.4 ± 5.9 96.3 ± 6.2 35.8 ± 3.4 60.7 ± 2.5 91.3 ± 8.2
Threonine 152.9 ± 8.5 139.6 ± 4.6 278.9 ± 22.0 152.8 ± 6.6 137.7 ± 5.6 290.2 ± 38.4 84.4 ± 4.0 87.6 ± 2.3 70.1 ± 16.4
Tryptophan 31.7 ± 2.6 53.7 ± 3.9 104.3 ± 5.2 166.2 ± 7.0 134.3 ± 5.8 120.7 ± 5.6 29.4 ± 1.6 48.6 ± 4.4 91.2 ± 7.4
Tyrosine 27.4 ± 2.4 29.6 ± 1.7 72.9 ± 5.4 36.4 ± 2.7 28.7 ± 3.3 71.8 ± 4.4 17.2 ± 1.2 21.3 ± 1.9 55.1 ± 4.5
Valine 98.3 ± 4.4 93.0 ± 4.0 103.9 ± 5.1 92 ± 2.5 86.8 ± 4.7 92.4 ± 4.5 273.3 ± 10.2 196.6 ± 5.9 151.3 ± 13.7
S
tr
ia
tu
m
Histidine 36.0 ± 0.9 53.1 ± 2.4 71.6 ± 6.4 39.1 ± 2.8 51.6 ± 3.9 70.9 ± 5.9 36.0 ± 1.5 47.7 ± 3.1 64.9 ± 7.7
Isoleucine 115.3 ± 4.8 105.6 ± 3.1 103.8 ± 9.1 105.7 ± 4.2 103.0 ± 3.8 101.4 ± 4.8 194.4 ± 10.3 158.7 ± 7.3 129.0 ± 10.6
Leucine 128.1 ± 5.7 120.7 ± 2.7 105.9 ± 8.1 110.8 ± 3.4 119.7 ± 4.2 108.8 ± 4.3 140.2 ± 6.0 144.6 ± 5.7 118.0 ± 6.7
Methionine 90.1 ± 3.5 96.5 ± 2.3 104.1 ± 5.1 84.9 ± 2.6 98.3 ± 1.2 103.3 ± 3.5 84.8 ± 3.1 91.3 ± 3.8 95.7 ± 2.2
Phenylalanine 39.6 ± 2.0 68.8 ± 2.7 98.3 ± 5.1 41.2 ± 4.0 63.1 ± 3.8 95.6 ± 4.5 34.1 ± 2.2 56.9 ± 3.0 83.2 ± 4.8
Threonine 124.0 ± 4.4 156.4 ± 3.7 201.6 ± 9.4 115.1 ± 3.9 157.6 ± 5.2 211.3 ± 14.3 76.3 ± 4.2 81.3 ± 3.1 59.8 ± 5.2
Tryptophan 34.6 ± 3.1 54.5 ± 3.2 34.6 ± 3.1 139.4 ± 5.6 127.6 ± 6.3 139.4 ± 5.6 27.5 ± 2.0 48.1 ± 2.9 27.5 ± 2.0
Tyrosine 27.8 ± 2.6 26.9 ± 1.6 68.7 ± 4.8 34.4 ± 3.1 26.0 ± 2.7 68.3 ± 5.2 15.0 ± 1.1 19.8 ± 1.7 54.7 ± 4.7
Valine 103.6 ± 4.2 98.9 ± 2.7 96.9 ± 6.3 94.4 ± 2.0 94.3 ± 3.8 96.0 ± 4.6 266.9 ± 6 211.9 ± 9.6 136.6 ± 10.6
Samples were collected at 2, 4, or 8 h (independent groups) after the oral gavage treatments. Values are expressed as percent of tap water control (mean ± SEM). Bold 
red and green values indicate a significant decrease or increase in the analyte, respectively as calculated by 1-way ANOVAs followed by Tukey’s posthoc, P < .05
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High Pressure Liquid Chromatography
Brain samples were mixed at a ratio of 1:5 (w/v) with 0.2 M per-
chloric acid and homogenized for 2 × 2 seconds with a probe soni-
cator (model UW2200; Bandelin Electronics) at 70% power. The 
samples were centrifuged at 4°C for 30 min at 21 000 x g and the 
supernatant transferred to Costar cellulose acetate filter tubes 
(0.22 µm; Corning Inc) and centrifuged at 4°C for 10 min at 21 000 x g.
For the measurement of DA, 5-HT, and norepinephrine (NE), 
the filtrate was injected directly into the high pressure liquid 
chromatography system. For the measurement of Tyr and Trp in 
the first experiment, 0.2 M perchloric acid was used to dilute the 
samples a further 80x. For the measurement of AAs in the second 
experiment, the samples were diluted a further 80x for Glu, Asp, 
Gln, Ser, Ala, Arg, Gly, His, and Met and 8x for the remaining AAs. 
Plasma samples were prepared by adding perchloric acid to yield 
a final concentration of 0.2 M and then underwent the same cen-
trifugation and filtration process as described for the brain sam-
ples. Plasma samples were diluted 100x for the measurement of 
Tyr and Trp in Experiment 1 as well as for the AAs in Experiment 2.
Chromatographic conditions were as follows: (1) for the neuro-
transmitter measurements in Experiments 1 and 2: equipment con-
sisted of Thermo Scientific Ultimate 3000 model isocratic pump and 
autosampler equipped with a Hypersi BDS C18 3 μm, 3 × 150 mm par-
ticle column kept at 28°C. Detection was carried out using a Thermo 
Scientific Dionex model 6011RS ultra Coulometric Analytical cell 
(E1: -150 mV: E2: +250 mV vs Pd reference). The column was main-
tained at 27  °C while eluting the analytes with a MDTM mobile 
phase (Thermo Scientific Dionex Test Phase, 70–3829) at a flow rate 
of 0.5 mL/min. (2) Tyr and Trp measurement in Experiment 1: the 
same conditions were used as in (1) but with cell potentials at E1: 
+250 mV: E2: +550 mV vs Pd reference. (3) AA profile in Experiment 
2: equipment consisted of Thermo Scientific Ultimate 3000 model 
4-line gradient pump, autosampler and fluorometric detector 
equipped with a Kinetex EVO C18 5 µm 4.6 × 150 mm particle col-
umn kept at 40°C. Mobile phase A  consisted of 10  mM Na2HPO4 
adjusted to pH 7.8 with phosphoric acid and filtered through a 
0.2-µm membrane under vacuum. Mobile phase B consisted of 1:1 
methanol to acetonitrile. The gradient was as follows: 5 min equili-
bration at 3% mobile phase B and gradually increased to 60% mobile 
phase B over 20 min followed by 100% mobile phase B for 3 min-
utes. The flow rate was 1 mL/min and detection was carried out at 
337 nm (excitation) and 442 nm (emission). The samples and stand-
ards underwent an in-needle precolumn o-phthaldialdehyde deri-
vatization reaction as previously described (Dionex  Corporation, 
2015). All mobile phase components, standards and reagents were 
purchased from Sigma Aldrich.
Behavioral Measurements
All behavioral tests were carried out at 3 to 4 h after the start 
of the dark phase. Testing in the dark phase was performed to 
ensure a consistently quiet testing environment throughout the 
study, and possibly a more natural behavior pattern due to rats 
being nocturnal. The rats were allowed at least 1 h to acclimatize 
to the testing rooms. Different cohorts of rats were used for dif-
ferent behavioral tests so that each rat was exposed to only one 
behavioral test, except for the locomotor activity test that was 
carried out before the forced swim test.
Amphetamine Induced Hyperlocomotion (AIH)
The AIH test is a widely used test for the detection of antimanic 
activity (Pereira et al., 2014). This test was developed based on the 
verification that amphetamine can induce mania-like symptoms in 
healthy individuals and mood stabilizers, as lithium and valproate, 
can reverse such amphetamine effects (Willson et al., 2005; Gould 
et al., 2007). Briefly, rats were placed in a square (1 x 1 m) arena with a 
video camera mounted above the arena. Baseline locomotor activity 
was recorded for 45 min, after which rats received an i.p. injection 
Table  2. The AA Composition of CGMP (Lacprodan CGMP-20) and 
Whey Protein (Lacprodan DI-9224) and the Amounts of AAs Received 
by a 300-g Rat at a Dose of 1500 mg/kg
CGMP Whey Protein
Composition 
(%)
Dose for  
300-g  
rat (mg)
Composition  
(%)
Dose for  
300-g rat (mg)
Alanine 6.6 29.7 5.6 25.2
Arginine 0.3 1.4 2.2 9.9
Apartate 3.4 15.3 11.5 5.2
Asparagine 2.2 9.9
Glutamate 12.2 54.9 18.6 8.4
Glutamine 2.8 12.6
Cysteine 0.1 0.5 2.5 11.3
Glycine 1.2 5.4 1.7 7.7
Histidine 0.1 0.5 1.8 8.1
Isoleucine 11.3 50.9 7.1 32.0
Leucine 2.4 10.8 11.5 51.8
Lysine 6.6 29.7 10.3 46.4
Methionine 2.2 9.9 2.5 11.3
Phenylalanine 0.2 0.9 3.2 14.4
Proline 12.8 57.6 6.9 31.1
Serine 8.1 36.5 5.2 23.4
Threonine 18.3 82.4 7.7 34.7
Tryptophan 0.1 0.5 1.8 8.1
Tyrosine 0.0 0.1 3.1 14.0
Valine 9.1 41.0 6.3 28.4
For whey protein, the aspartate and asparagine values as well as the glutamate 
and glutamine values are combined.
Table 3. Amino Acid Doses Received by a 300-g Rat for Amino Acid-
Depleting Treatments
Dose for a 300-g rat (mg)
CGMP1500 + Leu300
CGMP1500 +  
Leu300 + Trp45 BCAA Mix
Alanine 29.7 29.7 -
Apartate 15.3 15.3 -
Arginine 1.4 1.4 -
Asparagine 9.9 9.9 -
Cysteine 0.5 0.5 -
Glutamate 54.9 54.9 -
Glutamine 12.6 12.6 -
Glycine 5.4 5.4 -
Histidine 0.5 0.5 -
Isoleucine 50.9 50.9 135.0
Leucine 100.8 100.8 180.0
Lysine 29.7 29.7 -
Methionine 9.9 9.9 -
Phenylalanine 0.9 0.9 -
Proline 57.6 57.6 -
Serine 36.5 36.5 -
Threonine 82.4 82.4 -
Tryptophan 0.5 14.0 -
Tyrosine 0.1 0.1 -
Valine 41.0 41.0 135.0
Total 540.1 553.6 450.0
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of amphetamine (1 mg/kg) and were placed back into the arena to 
record locomotor activity for a further 45  min. One group of rats 
received a saline injection (and tap water oral gavage) to demonstrate 
amphetamine-induced hyperlocomotion. The distance moved (cm) 
by each rat was measured using EthoVision XT video tracking soft-
ware (version 12; Noldus Information Technology, Waacheningen, 
The Netherlands), and the data were collapsed into 5-min bins.
Pre-Pulse Inhibition (PPI)
The PPI test was carried out as previously described (Hougaard 
et  al., 2011). Briefly, the PPI testing was carried out in 2 cham-
bers (San Diego Instruments) with 70 dB(A) white background 
noise. Animal movement was transduced from the test tubes 
(∅ 8.2 cm) through a piezoelectric accelerometer. The test session 
consisted of 5 min acclimatization; 5 startle stimuli of 120 dB; 35 
randomized pre-pulse, startle, and no stimuli (10 startle stimuli 
of 120 dB(A); 5 each of 4 different levels of pre-pulses plus star-
tle stimulus [72,74, 78, and 86 dB(A), denoted PPI72, PPI74, PPI78, 
and PPI86], and 5 trials with background noise only) followed by 
5 final startle stimuli of 120 dB(A). The individual stimuli were 
randomized between 10 and 20 s (mean 15 s). The average amp-
litude (AVG) of the startle response was calculated as the mean 
of the 5 initial (AVGinitial), 10 middle (AVGmiddle), and 5 final (AVGfinal) 
stimuli for each of the exposed groups. PPI was expressed as per-
cent reduction in the averaged 5 AVGs for each PPI compared with 
the average of the 10 middle startle trials: %PPI = 100 − [(AVG at 
pre-pulse + startle trial)/(AVG at startle trial)] × 100%.
Elevated Plus Maze (EPM)
The EPM is widely used for the screening of anxiolitic- or anx-
iogenic-like effects of drugs. The test was carried out as pre-
viously described (Fischer et  al., 2012). The maze was 80  cm 
above the ground with 2 opposite open arms and 2 closed arms 
measuring 50 cm × 10 cm. Rats were placed in the center of the 
maze facing one of the closed arms. Circadian rhythm has been 
shown to affect rodent behavior in the EPM (Jones and King, 
2001; Bertoglio and Carobrez, 2002), and care should therefore 
be exercised when directly comparing these EPM results with 
light-phase studies. The time spent by the rats in the open arms 
of the maze was measured during a 5-min test session using 
EthoVision XT video tracking software.
Forced Swim Test (FST)
The FST is a widely used test for screening of antidepressant-like 
activity (Slattery and Cryan, 2012). The animals were exposed to 
the FST as previously described (Liebenberg et al., 2015; Kirkedal 
et  al., 2017). The animals were placed individually to swim in 
acrylic cylinders (24 cm diameter x 60 cm high containing 40 cm 
of water at 24 ± 1ºC) for 15 min (pre-test). After 24 h the animals 
were exposed to a 5-min test session that was recorded and later 
analyzed by an independent scorer blinded to the treatment 
groups. After each trial, the water of the cylinders was exchanged.
Open Field Test (OFT)
The OFT is widely used for assessing locomotor activity and as a 
tool to identify false-positive effects in tests that are dependent on 
the locomotor activity such as the FST (Slattery and Cryan, 2012). 
Immediately before the FST, the rats were placed in an open field arena 
(1m x 1m with 40-cm-high walls) for 5 min as previously described 
(Liebenberg et al., 2010). The total distance moved (cm) was quanti-
fied using Noldus Ethovision XT12 (Noldus Information Technology, 
Waacheningen, The Netherlands) video tracking software.
Data Analysis and Statistics
For DA, 5-HT, NE, and AA measurements, 1-way ANOVAs (fol-
lowed by Tukey’s posthoc tests where appropriate) were used. 
The AA analyses were not corrected for multiple comparisons, 
but the repeatable patterns across sample types and time points 
indicate that the changes were not due to chance effects. For 
the AIH and PPI tests, repeated measures 1-way ANOVAs were 
performed. For the EPM, FST, and OFT, 1-way ANOVAs followed 
by Tukey’s posthoc tests were used where appropriate. Statistics 
were calculated using SPSS (version 22, SPSS Inc). The ANOVA 
results for the behavioral tests are stated in the Results section, 
and the ANOVA results for amino acid and neurotransmitter 
analyses are given in Supplementary Tables 1 and 2.
Study Design
Experiment 1: Dose-Determination and the Effects of 
Supplementing CGMP with Leu
Rats were treated with a low (1500 mg/kg) or high (3000 mg/kg) 
dose of CGMP via a single oral gavage administration. Two hours 
later, plasma and brain samples (hippocampus and frontal cor-
tex) were collected to investigate the depleting action on brain 
and plasma Tyr, Trp, and brain DA and 5-HT. To investigate the 
additive depleting effect of Leu, separate groups of rats were 
treated with CGMP (1500  mg/kg) + Leu (300  mg/kg) or CGMP 
(3000  mg/kg) + Leu (600  mg/kg). A  BCAA mixture, Leu (600  mg/
kg) + Ile (450 mg/kg) + Val (450 mg/kg), was used as a positive con-
trol and tap water as a negative control. A group treated with 
whey protein (1500  mg/kg) was included as a reference. Tap 
water controls had n = 18 and the other treatments had n = 8.
Experiment 2: Time Dependency, Effects Supplementing with 
Trp, and a More Complete AA Profile
Rats were treated with a single oral gavage with CGMP (1500 mg/
kg) + Leu (300 mg/kg) at 2, 4, or 8 h before decapitation. Plasma 
and brain samples (hippocampus, frontal cortex, and stri-
atum) were collected to measure DA, 5-HT, NE, histidine (His), 
Ile, Leu, methionine (Met), Phe, threonine (Thr), Trp, Tyr, and 
Val. To explore whether a selective Tyr/Phe/DA depletion can be 
attained by supplementing with Trp, a group of rats was treated 
with CGMP (1500  mg/kg) + Leu (300  mg/kg) + Trp (45  mg/kg) at 
the same time points. A  BCAA mixture, Leu (600  mg/kg) + Ile 
(450 mg/kg) + Val (450 mg/kg), was used as a positive control and 
tap water as a negative control. Group sizes were n = 8 to 10.
Experiment 3: Behavioral Effects of CGMP
The same treatments used in Experiment 2 were used in the 
Experiment 3 with the inclusion of a whey protein (1500  mg/
kg) control. To investigate acute effects, rats were exposed to a 
behavioral test at 2 or 8 h after a single oral gavage treatment. 
To investigate the effects of repeated treatments, rats were 
exposed to a behavioral test after 1 week of daily administration 
and 8 h after the final treatment. The behavioral tests used were 
as follows: AIH (manic-like behavior), PPI (schizophrenia-like 
behavior), EPM (anxiety-like behavior) and FST (depression-like 
behavior). Group sizes were n = 10 to 12.
RESULTS
Experiment 1: Dose Determination and the Effects of 
Supplementing CGMP with Leu
Both Tyr and Trp were significantly depleted (P < .001) by all treat-
ments in the hippocampus, frontal cortex, and plasma, except 
Downloaded from https://academic.oup.com/ijnp/article-abstract/21/5/473/4904468
by Danish Regions user
on 14 May 2018
478 | International Journal of Neuropsychopharmacology, 2018
for whey protein, which induced an increase in Trp in brain and 
plasma (P < .001) (Figure 1). DA levels were significantly reduced 
by CMGP 1500 mg/kg to 71.7% of control in the hippocampus and 
by CGMP 1500 mg/kg + Leu 300 mg/kg to 80.1% of control in the 
frontal cortex (P < .05) (Figure 1). The 5-HT levels in both the hip-
pocampus and frontal cortex were depleted by the treatments 
(P < .01), except by whey protein (Figure 1). The CGMP (1500 mg/
kg) + Leu (300 mg/kg) treatment was the most efficient treatment 
to reduce the levels of Tyr, Trp, DA, and 5-HT. The increase in Trp 
(to approximately 134% of control in brain and 167.1% of control 
in plasma) after whey protein treatment is likely explained by 
the relatively high content of Trp in whey compared with CGMP 
(see Table 2). The ANOVA results for Experiment 1 are summa-
rized in Supplementary Table 1.
Experiment 2: Time Dependency, the Effects of Trp 
Supplementation, and a More Detailed AA Profile
CGMP (1500  mg/kg) + Leu (300  mg/kg) and the BCAA mixture 
depleted Tyr, Trp, and Phe after 2 h in plasma and brain, started 
to normalize after 4 h, and returned to control levels after 8 h, 
except for Tyr, which remained reduced in both plasma and brain 
(Table 1). By adding Trp (45 mg/kg) to CGMP + Leu, the depletion 
of Trp was prevented and induced a significant increase in Trp 
levels (in plasma and brain (Table 1).
The Tyr + Phe plasma availability ratio was significantly 
reduced after 2, 4, and 8 h by all treatments (see Supplementary 
Table  4). The Trp plasma availability ratio was significantly 
reduced by CGMP (1500 mg/kg) + Leu (300 mg/kg) and the BCAA 
mixture after 2 and 4 h, but not after 8 h, and was significantly 
increased by CGMP (1500 mg/kg) + Leu (300 mg/kg) + Trp (45 mg/
kg) after 2 h, but not after 4 or 8 h. The DA and 5-HT tissue lev-
els appeared to correlate with the plasma availability ratios of 
Tyr+Phe and Trp respectively, but a reduced Tyr+Phe availability 
ratio outlasted lowered DA brain levels, which were not signifi-
cantly affected after 8 h.
In agreement with the effects observed in Experiment 1, 
CGMP + Leu and the BCAA mixture induced a modest but signifi-
cant decrease in DA levels in the frontal cortex after 2 h (respect-
ively 74.4% and 66.9% of control, P < .05) and remained significant 
at 4 h after treatment (respectively 77.5% and 72.4% of control, 
P < .01) (Figure 2). 5-HT levels were depleted by CGMP + Leu and 
the BCAA mixture in the hippocampus, frontal cortex, and stri-
atum after 2 h (P < .01), started to return to baseline at 4 h, and 
normalized after 8 h (Figure 2). NE remained relatively unaffected 
by the treatments; however, there was a tendency for the treat-
ments to increase NE levels in the striatum, which was signifi-
cant after 2 h (P < .05) (Supplementary Figure 1).
The levels of several other AAs were altered by the treat-
ments used in the study (Table 1): Leu, Ile, and Val levels were 
elevated by the BCAA mixture in plasma and brain, whereas 
CGMP + Leu increased the levels of Thr (Table 1), which is abun-
dant in CGMP as can be seen in Table 1. In addition, His, which 
is lacking in CGMP, was reduced in plasma and brain (Table 1).
The ANOVA results for Experiment 2 are provided in 
Supplementary Table 2.
Figure 1. The effects on Tyr and Trp in plasma and Tyr, Trp, DA, and 5-HT in the hippocampus and frontal cortex by tap water, CGMP (1500 mg/kg), CGMP (3000 mg/
kg), CGMP (1500 mg/kg) + Leu (300 mg/kg), CGMP (3000 mg/kg) + Leu (600 mg/kg), BCAA mixture (i.e. Leu 600 mg/kg + Ile 450 mg/kg + Val 450 mg/kg), or whey protein 2 h 
after oral gavage treatment. Values are expressed as percent of tap water control (mean ± SEM). 1-way ANOVA followed by Tukey’s posthoc; *P < .05, #P < .01, @P < .001.
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Experiment 3: Behavioral Effects of CGMP
AIH
Between-subjects repeated ANOVAs revealed significant over-
all treatment effects on distance moved at 2  h after acute 
treatment (F(4, 45) = 2.925, P = .031) and after 1 week of chronic 
treatment (F(4, 45) = 3.016, P = .028) following the amphetamine 
injection (Figure 3). The overall treatment effect after 8 h was 
not significant (F(4, 45) = 0.576, P = .682). The 2-h treatment group 
injected with saline was excluded from the ANOVA. Before the 
amphetamine injection, there were no significant overall treat-
ment effects at 2 h (F(4, 45) = 0.849, P = .502) or 8 h (F(4, 45) = 1.527, 
P = .211) after acute treatment. However, there was a significant 
overall treatment effect before amphetamine administration 
after 1 week of chronic treatment (F(4, 45) = 2.895, P = .032).
PPI
There were no significant overall treatment effects on %PPI at 2 h 
(F(4, 54) = 0.183, P = .946) or 8 h (F(4, 52) = 0.602, P = .663) after acute 
treatment, or after 1 week of chronic treatment (F(4, 53) = 0.332, 
P = .855). A 1-way ANOVA comparing the mean %PPI of all treat-
ments at different dB levels revealed significant differences 
at 2 h (F(3, 232) = 101.59, P < .001) and 8 h after acute treatment 
(F(3, 224) = 134.55, P < .001) and after 1 week of chronic treatment 
(F(3, 236) = 118.31, P < .001).
EPM
There were no significant overall treatment effects on the time 
spent in the open arms at 2  h (F(4, 55) = 0.257, P = .904) or 8  h 
(F(4, 54) = 0.668, P = .617) after acute treatment, or after 1 week of 
chronic treatment (F(4, 55) = 1.580, P = .193). Although not signifi-
cant, CGMP + Leu increased the time spent in the open arms by 
45% at 8 h following an acute treatment (Figure 4).
FST
There were no overall treatment effects on immobility at 2  h 
(F(4, 54) = 0.509, P = .730) or 8 h (F(4, 52) = 1.994, P = .109) after acute 
Figure 2. The time-dependent effects on DA and 5-HT levels in the hippocampus, frontal cortex, and striatum by tap water, CGMP (1500 mg/kg) + Leu (300 mg/kg), CGMP 
(1500 mg/kg) + Leu (300 mg/kg) + Trp (45 mg/kg), or BCAA mixture (Leu 600 mg/kg + Ile 450 mg/kg + Val 450 mg/kg) at 2, 4 or 8 h after the oral gavage treatments. Values are 
expressed as percent of tap water control (mean ± SEM). 1-way ANOVA followed by Tukey’s posthoc; *P < .05, #P < .01, @P < .001.
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treatment, or after 1 week of chronic treatment (F(4, 53) = 1.269, 
P = .294). Although not significant, CGMP + Leu + Trp (P = .032) and 
the BCAA mixture (P = .014) reduced immobility time respec-
tively by 18% and 26% at 8 h after acute treatment.
OFT
There were no significant overall treatment effects on the dis-
tance moved at 2 h (4, 55) = 1.804, P = .141) or 8 h (F(4, 52) = 1.830, 
P = .137) after acute treatment or after 1 week of chronic treat-
ment (F(4, 54) = 1.836, P = .135).
Discussion
The main finding in the present work is that CGMP induced 
a time-dependent reduction in Tyr, Trp, and Phe in brain and 
plasma, which was augmented by supplementing with Leu. 
CGMP + Leu reduced DA in the frontal cortex and 5-HT in the 
hippocampus, frontal cortex, and striatum after 2 and 4  h. 
CGMP + Leu also had antimanic activity in the amphetamine-
induced hyperlocomotion test at 2 h after a single acute treat-
ment and after 1 week of chronic treatment.
Theoretically, there are at least 2 possible mechanisms 
through which CGMP, Phe/Tyr/Trp-free AA mixtures, and BCAA 
mixtures may induce the depletion of central Phe, Tyr, and 
Trp. Firstly, the ingested AAs (especially Leu) would stimulate 
peripheral protein synthesis leading to the residual AAs that 
are absent in the mixture (i.e., Phe, Tyr, and/or Trp) to become 
depleted in plasma. Secondly, Phe, Tyr, and Trp use the same 
transporter and therefore compete for entry into the brain with 
other LNAAs (His, Ile, Leu, Met, Thr, and Val), and their relatively 
Figure 3. The time-dependent effects on the behavioral responses of rats exposed to the AIH or PPI tests by tap water, CGMP (1500 mg/kg) + Leu (300 mg/kg), CGMP 
(1500 mg/kg) + Leu (300 mg/kg) + Trp (45 mg/kg), BCAA mixture (Leu 600 mg/kg + Ile 450 mg/kg + Val 450 mg/kg), or whey protein (1500 mg/kg). Independent groups of 
rats were exposed to the AIH or PPI after 2 h, 8 h, or 1 week (daily) of oral gavage treatment. Values are expressed as the mean ± SEM. 1-way ANOVA followed by Tukey’s 
posthoc, *P < .05.
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lower plasma levels causes them to be outcompeted and further 
reduced in the brain. The rate-limiting enzymes that synthesize 
DA and 5-HT, tyrosine hydroxylase and tryptophan hydroxylase 
respectively, are unsaturated under normal physiological condi-
tions, and the rate of monoamine synthesis is therefore vulner-
able to changes in Tyr and Phe availability.
In this study, we found that the CGMP+Leu- and BCAA 
mixture-induced depletion of Phe, Tyr, and Trp induced an 
antimanic-like effect in the AIH test at the same time-point 
at which Tyr, Phe, Trp, and DA levels in the brain are reduced, 
namely at 2 h, but not at 8 h after a single oral dose, although the 
Tyr+Phe plasma availability ratio was still significantly reduced 
8 h after treatment. After 2 h, DA was reduced in frontal cortex 
by CGMP+Leu, whereas DA was reduced in the frontal cortex 
and striatum by the BCAA mixture. One other study has also 
observed an antimanic-like effect in the AIH test after acute i.p. 
administration of a BCAA mixture (Le Masurier et al., 2006). That 
the antimanic effect was still present when CGMP+Leu was sup-
plemented with Trp and thereby prevented 5-HT depletion, sug-
gests that it may have been mediated by a decrease in DA rather 
than 5-HT. This is despite the observation that the depletion of 
5-HT was more pronounced than that of DA. NE levels remained 
relatively unaffected by the treatments in frontal cortex and hip-
pocampus, with a trend for increased NE observed in striatum 
for the depleting treatments (see Supplementary Figure 1). These 
results suggest that NE levels in the brain regions investigated 
here may be less sensitive to Tyr and Phe depletion than DA.
Daily treatment with CGMP+Leu (±Trp) for 1 week had a 
cumulative antimanic-like effect, since the effect in the AIH test 
was present at 8 h after the final dose, a time-point that was 
devoid of any effect after a single treatment. A 1-week chronic 
treatment group was not included for the AA and monoamine 
analysis, and therefore it is not possible to correlate the anti-
manic-like activity after chronic treatment to AA and mono-
amine levels. However, the activity at 8 h post-gavage may be 
related to sustained altered amino acid availability after chronic 
treatment, or to secondary effects induced by sustained fluctua-
tions in amino acid availability over a 1-week period. It therefore 
appears that CGMP may have potential for chronic antimanic 
use, although supplementing with natural protein at some 
meals would be needed to ensure that their nutritional require-
ments of all essential amino acids are met over longer periods of 
treatment. It is important to note that while only the BCAA mix-
ture significantly lowered striatal DA, AIH was also significantly 
Figure 4. The time-dependent effects on the behavioral responses of rats exposed to the EPM or FST tests by tap water, CGMP (1500 mg/kg) + Leu (300 mg/kg), CGMP 
(1500 mg/kg) + Leu (300 mg/kg) + Trp (45 mg/kg), BCAA mixture (i.e. Leu 600 mg/kg + Ile 450 mg/kg + Val 450 mg/kg), or whey protein (1500 mg/kg). Independent groups 
of rats were exposed to the EPM or FST after 2 h, 8 h, or 1 week (daily) of oral gavage treatment. Values are expressed as the mean ± SEM. 1-way ANOVA followed by 
Tukey’s posthoc, P > 0.05.
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reduced by CGMP (1500 mg/kg) + Leu (300 mg/kg) acutely at 2 h 
and 8 h after chronic treatment. Therefore, this study does not 
provide a clear correlation between tissue DA levels and AIH.
The results from the EPM produced some interesting results. 
At 8  h after a single dose, there was a trend for CGMP+Leu 
to induce an anxiolytic-like effect, but not at 2  h (Figure  4). 
However, after 1 week of daily treatment (8 h after the final dose), 
a Student’s t test revealed a significant increase in the time 
spent in the open arms, suggesting that CGMP+Leu may exert 
an anxiolytic-like effect. Nonetheless, unlike its antimanic-like 
activity, it appeared that its anxiolytic-like action may have been 
mediated to a greater degree by 5-HT depletion, since Trp sup-
plementation appeared to suppress the effect. This is in contrast 
to clinical studies that found that depletion of Trp by consum-
ing Trp-free AA mixtures increased anxiety scores (Klaassen 
et al., 1998; Monteiro-dos-Santos et al., 2000; Argyropoulos et al., 
2004). This said, the anxiolytic potential of CGMP warrants fur-
ther investigation.
We did not observe any significant behavioral effects of any of 
the treatments on the FST after depletion of Phe+Tyr and/or 5-HT. 
This was not unexpected, since previous studies investigating 
Trp depletion did not report changes in the FST (van Donkelaar 
et al., 2010), although one study did find that chronic Trp deple-
tion by a low-Trp diet increased immobility in the rat FST after 
14 d but not after 7 d (Franklin et al., 2012). As mentioned in the 
Introduction, Trp depletion also does not appear to affect mood 
in healthy subjects (Benkelfat et al., 1994). As far as we are aware, 
the effect of Phe and Tyr depletion has not been investigated in 
the rodent FST as yet, whereas Phe and Tyr depletion studies in 
humans did not find notable changes in mood, although reward 
and cognition was reported to be negatively affected (McLean 
et al., 2004; McTavish et al., 2005; Roiser et al., 2005).
We did not observe notable effects in the PPI test, commonly 
used to identify schizophrenia-related behavior (Figure 3). The 
effects of dietary depletion of Phe+Tyr and/or 5-HT on PPI in 
rodents have not been investigated to our knowledge. However, 
a clinical study has shown that selective Phe+Tyr depletion 
had no effect, whereas selective Trp depletion and combined 
Phe+Tyr+Trp depletion led to a reduction in PPI in healthy 
humans (Mann et al., 2008). Our results did not confirm these 
findings, but given the known role of DA and 5-HT in the patho-
physiology of schizophrenia (Geyer et  al., 2001; Dean, 2003; 
Laruelle et al., 2003), alterations in monoamine function through 
dietary depletion of the precursor AAs cannot be ruled out.
In addition to the depletion of Phe, Tyr, and Trp, CGMP could 
theoretically also deplete other AAs it lacks by activating pro-
tein synthesis (see Table 1). As can be seen in Table 2, His was 
depleted by CGMP+Leu±Trp at 2 and 4 h after a single dose. This 
AA is the precursor for His, which is known to play a critical role 
in wakefulness and has also been associated with a number of 
clinical disorders in which cognitive performance is impaired 
(reviewed in Onodera et al., 1994). A study that investigated the 
effects of dietary His depletion in humans found that although 
its depletion impaired psychomotor performance, wakefulness 
was not affected (van Ruitenbeek et al., 2009).
In conclusion, this study shows that CGMP (supplemented 
with Leu) administered orally to rats induces a robust but tran-
sient depletion of Phe, Tyr, and Trp in plasma and brain tissue, 
lowers the levels of DA and 5-HT in the brain, and induces an 
antimanic-like effect. However, the treatments did not lower 
brain tissue DA without also lowering tissue 5-HT, and therefore 
the study does not distinguish between DA- and 5-HT-induced 
effects. It should be noted that the results presented here are 
circumstantial evidence for a mechanistic link between DA 
and 5-HT levels in the brain and an antimanic effect, and cau-
tion should therefore be exercised when making conclusions 
based solely on these results. The reductions observed in total 
tissue DA levels were marginal, and experiments measuring 
extracellular as opposed to total tissue neurotransmitter levels 
may give a more detailed picture of the mechanisms involved. 
Nevertheless, preclinical and clinical studies to investigate the 
potential of CGMP as an adjunctive treatment for mania and 
possibly also other psychiatric conditions are warranted.
Supplementary Items
Supplementary Table 1. The ANOVA results for treatment effects 
on plasma and brain levels of dopamine, serotonin, tyrosine, 
and tryptophan in Experiment 1.
Supplementary Table  2. The ANOVA results for treatment 
effects on plasma and brain levels of neurotransmitters, tryp-
tophan, tyrosine, other large neutral amino acids, as well as 
Tyr+Phe and Trp plasma availability ratios in Experiment 2.
Supplementary Table  3. Tap water control mean values for 
neurotransmitters, tryptophan, tyrosine, and other large neutral 
amino acids in Experiment 2, expressed as mean ± SEM µg/g tis-
sue (brain tissue) or as mean ± SEM µM (plasma).
Supplementary Table 4. The effects of treatment on the plasma 
availability ratios of tyrosine + phenylalanine (Tyr+Phe) and tryp-
tophan (Trp) expressed as the availability ratio and as the avail-
ability ratio as percent of tap water control. The mean plasma 
concentrations (µM) of amino acids for the different treatment 
group were used to calculate the availability ratios according to 
using the following equations: Tyr+Phe availability = ([Tyr] + [Phe]) / 
([Trp] + [LNAAs]), and Trp availability = [Trp] / ([Tyr] + [Phe] + 
[LNAAs]), where [LNAAs] is the sum of the concentrations of the 
other large neutral amino acids histidine (His), isoleucine (Iso), 
leucine (Leu), methionine (Met), threonine (Thr), and valine (Val). 
Red and green values indicate a significant decrease or increase 
in the ratio, respectively, as calculated by 1-way ANOVAs fol-
lowed by Tukey’s posthoc, P < .05.
Supplementary Figure  1. The time-dependent effects on NE 
levels in the hippocampus, frontal cortex, and striatum by tap 
water, CGMP (1500  mg/kg) + Leu (300  mg/kg), CGMP (1500  mg/
kg) + Leu (300 mg/kg) + Trp (45 mg/kg) or BCAA mixture (i.e. Leu 
600  mg/kg + Ile 450  mg/kg + Val 450  mg/kg). Samples were col-
lected at 2, 4, or 8 h after the oral gavage treatments. Values are 
expressed as % of tap water control (mean ± SEM).
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